You are here: Industry Insights > Mavacamten

News List

LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update LianBio
March 31, 2022
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets...
BMS acquires biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
November 19, 2020
Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.
MyoKardia Receives Breakthrough Therapy Designation for Mavacamten americanpharmaceuticalreview
July 30, 2020
MyoKardia announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy.
Obstructive Hypertrophic Cardiomyopathy Study from MyoKardia Meets Primary, Secondary Endpoints americanpharmaceuticalreview
May 15, 2020
MyoKardia announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Sanofi and MyoKardia end heart disease drug collaboration pharmatimes
January 04, 2019
Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.
MyoKardia transforms inherited heart disease symptoms in midstage trial fiercebiotech
August 08, 2017
An estimated 70,000 patients could potentially benefit from mavacamten if approved